Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2008-04-01
2008-04-01
Bernhardt, Emily (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S364000, C544S370000
Reexamination Certificate
active
07351828
ABSTRACT:
The present invention relates to the use of compounds of formula (I)for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
REFERENCES:
patent: 3362956 (1968-01-01), Archer
patent: 3472854 (1969-10-01), Archer
patent: 5714498 (1998-02-01), Kulagowski et al.
patent: 5714854 (1998-02-01), Mizuta et al.
patent: 5792768 (1998-08-01), Kulagowski et al.
patent: 6960589 (2005-11-01), Cowart et al.
patent: 2002/0169166 (2002-11-01), Cowart et al.
patent: 2003/0008878 (2003-01-01), Cowart et al.
patent: 0 468 884 (1991-07-01), None
patent: 0 882 718 (1998-12-01), None
patent: 2 154 605 (1999-09-01), None
patent: 98/31368 (1998-07-01), None
patent: 00/23056 (2000-04-01), None
patent: 02/88093 (2002-11-01), None
Sule et al. Chemical Abstracts, vol. 90 No. 204028 (1979).
Sule et al. Bull Haff Instt, vol. 6, pp. 62-64 (1978).
Andersson, K. et al., “Physiology of penile erection,” Physiol. Rev. 75:191-236, 1995.
Bendele, A.M. et al., “Anti-Inflammatory Activity of Pergolide, a Dopamine Receptor Agonist,” Journal of Pharmacology and Experimental Therapeutics 259(1):169-175 (1991).
Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977).
Chen, F.F. et al., “Effects of dopamine, Apomorphine, -Hydroxybutyric Acid, Haloperidol and Pimozide on Reflex Bradycardia in Rats,” Journal of Pharmacology and Experimental Therapeutics 214(2):427-432 (1980).
DeGroat, W. et al., “Neural Control of Penile Erection, in : Nervous control of urogenital system,” Hardwood Academic Publishers, Chur, Switzerland, vol. 3 (ed. Maggi, C.):467-524 (1993).
Dula, E. et al., “Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction,” Urology 56:130-135 (2000).
Hahn, R.A. et al., “Primate Cardiovascular Responses Mediated by Dopamine Receptors: Effects of N, N-di-n-Propyldopamine and LY171555,” Journal of Pharmacology and Experimental therapeutics 229(1):132-138 (1984).
Harris, M. C. et al., “Sequential N-Arylation of Primary Amines as a Route to Alkyldiarylamines,” J. Org. Chem. 64:6019-6022 (1999).
Hrib, N. J., et al., “The dopamine D4receptor: a controversial therapeutic target,” Drugs of the Future 2000 25(6):587-611.
Koch, V. et al., “Chemistry of 3-Hydroxypyridien part 2: Synthesis of 5,6-Dihalo-3hydroypyridines,” Synthesis 499-501 (1990).
Lissoni, et al., “Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia,” Neuroendocrinology Letters ISSN 21:405-408 (2000).
Lynch, J.K. et al., “Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic,” Tetrahedron: Asymmetry 9:2791-2794 (1998).
Melis, M et al., “Dopamine and Sexual Behavior,” Neurosience and Biobehavioral Reviews, 19(1):193-35 (1995).
Milligan, G. et al., “Chimaeric G proteins: their potential use in drug discovery,” Trends Pharmacol Sci 20:118-124 (1998).
Missale, C. et al. “Dopamine receptors: from structure to function,” Pl•ysiol Rev 78:189-225 (1998).
Morales, A. et al., “Oral and Topical Treatment of Erectile Dysfunction: present and future,” Urologic Clinics of North America, vol. 22:879-886 (1995).
Moreland, RB, et al., “Prospectives for Pharmacotherapy of Male Erectile Dysfunction,” Curr Opinion CPNS Invest Drugs, 2:283-302 (2000).
Padma-Nathan, H. et al., “Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction,” Urology 161:214 (abstract 821) (1999).
Primus, R. et al., “Localization and characterization of dopamine D4binding sites in rat and human brain by use of the novel D4receptor-selective ligand [3H]NGD 94-1,” J. Pharmacol Exp. Ther 282:1020-1027 (1997).
Sule, D.P. et al., “Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6)—substituted benzimidazoles,” Bull. Haffkine Inst. 6(2):62-64 (1978).
Suzuki, M. et al., “D3dopamine receptor mRNA is widely express in human brain,” Brian Res 779:58-74 (1998).
Vallone, D. et al., “Structure and function of dopamine receptors,” Neurosci Biobehav. Rev. 24:125-132 (2000).
Wagaw, S. et al., “The Synthesis of Aminopyridines: A Method Employing Palladium-Catalyzed Carbon-Nitrogen Bond Formation,” J. Org. Chem 61:7240-7241 (1996).
Yang B. et al., “Palladium-catalyzed amination of aryl halides and sulfonates,” Journal of Organometallic Chemistry 576:125-146 (1999).
“IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry,” Pure Appl. Chem. 45:13-30 (1976).
Bivalacqua et al., “Pharmacotherapy for erectile dysfunction,” TIPS 21:484-489 (2000)
Shvedov et al., “Catalytic alkylation of amines with alcohols,” Zhumal Organicheskoi Khimii 6(9):1838-1840 (1970).
Pugsley et al., “The discovery of PD89211 and related compounds: selective dopamine D4 receptor antagonists,” Progress in Neuro-Psychopharmacology & Biological Psyciatry 26(2):219-226 (2002).
Bhatia Pramila A.
Brioni Jorge D.
Cowart Marlon D.
Daanen Jerome F.
Kolasa Teodozyj
Abbott Laboratories
Bernhardt Emily
Gabryleda Ferrari Dileo
LandOfFree
Benzimidazoles that are useful in treating sexual dysfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazoles that are useful in treating sexual dysfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazoles that are useful in treating sexual dysfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2762726